Robin LaChapelle's most recent trade in ArriVent BioPharma Inc. was a trade of 6,503 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 6,503 | 6,370 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 11 Jul 2025 | 6,503 | 135,736 | - | 2.3 | 14,827 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 2,600 | 12,873 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 11 Jul 2025 | 2,600 | 129,233 | - | 2.3 | 5,928 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 11 Jul 2025 | 2,050 | 126,633 | - | 2.3 | 4,674 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 2,050 | 410 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 12,364 | 18,865 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.65 per share. | 19 Sep 2024 | 12,364 | 124,583 | - | 3.7 | 45,129 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 7,164 | 15,473 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 19 Sep 2024 | 7,164 | 109,748 | - | 2.3 | 16,334 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 2,867 | 22,637 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 19 Sep 2024 | 2,867 | 102,584 | - | 2.3 | 6,537 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.24 per share. | 19 Sep 2024 | 2,700 | 99,717 | - | 6.2 | 16,848 | Common Stock |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 2,700 | 56,471 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 2,471 | 2,460 | - | - | Stock Option (right to buy) | |
| ArriVent BioPharma Inc. | Robin LaChapelle | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. | 19 Sep 2024 | 2,471 | 112,219 | - | 2.3 | 5,634 | Common Stock |